160 related articles for article (PubMed ID: 23142220)
1. Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
Herth I; Witzens-Harig M; Beckhove P; Hose D; Meissner T; Neuber B; Engelhardt M; Haas J; Neben K; Ho AD; Klein B; Goldschmidt H; Hundemer M
Exp Hematol; 2013 Mar; 41(3):231-40. PubMed ID: 23142220
[TBL] [Abstract][Full Text] [Related]
2. Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.
Rew SB; Peggs K; Sanjuan I; Pizzey AR; Koishihara Y; Kawai S; Kosaka M; Ozaki S; Chain B; Yong KL
Clin Cancer Res; 2005 May; 11(9):3377-84. PubMed ID: 15867238
[TBL] [Abstract][Full Text] [Related]
3. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
4. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
[TBL] [Abstract][Full Text] [Related]
5. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
[TBL] [Abstract][Full Text] [Related]
6. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.
Svane IM; Nikolajsen K; Johnsen HE
Scand J Immunol; 2007 Oct; 66(4):465-75. PubMed ID: 17850592
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.
Neuber B; Herth I; Tolliver C; Schoenland S; Hegenbart U; Hose D; Witzens-Harig M; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunol; 2011 Jul; 187(2):1047-56. PubMed ID: 21677134
[TBL] [Abstract][Full Text] [Related]
8. CD8+ T cells reactive to survivin antigen in patients with multiple myeloma.
Grube M; Moritz S; Obermann EC; Rezvani K; Mackensen A; Andreesen R; Holler E
Clin Cancer Res; 2007 Feb; 13(3):1053-60. PubMed ID: 17289902
[TBL] [Abstract][Full Text] [Related]
9. [Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus].
Stanislav ML; Balabanova RM; Nikonova MF; Litvina MM; Iarilin AA
Ter Arkh; 2000; 72(5):44-9. PubMed ID: 11109620
[TBL] [Abstract][Full Text] [Related]
10. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
11. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
12. [Effects of thalidomide on CD4(+)CD25(+) T regulatory cells in patients with multiple myeloma].
Yang Y; Zhang WG; He AL; Yang HY; Wang JL; Tian W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):538-42. PubMed ID: 18549624
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive phenotypic analysis of the gut intra-epithelial lymphocyte compartment: perturbations induced by acute reovirus 1/L infection of the gastrointestinal tract.
Bharhani MS; Grewal JS; Peppler R; Enockson C; London L; London SD
Int Immunol; 2007 Apr; 19(4):567-79. PubMed ID: 17369189
[TBL] [Abstract][Full Text] [Related]
14. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.
Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI
Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341
[TBL] [Abstract][Full Text] [Related]
15. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma.
Gupta R; Ganeshan P; Hakim M; Verma R; Sharma A; Kumar L
Leuk Res; 2011 Jul; 35(7):874-8. PubMed ID: 21146215
[TBL] [Abstract][Full Text] [Related]
16. Functional CD4(+) and CD8(+) T-cell responses induced by autologous mitomycin C treated Epstein-Barr virus transformed lymphoblastoid cell lines.
Meij P; Bloemena E; Palmen N; Brink A; Vervoort MB; Meijer CJ; Middeldorp JM
Cell Immunol; 2001 Feb; 208(1):25-33. PubMed ID: 11277616
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.
Zou J; Rudwaleit M; Brandt J; Thiel A; Braun J; Sieper J
Arthritis Rheum; 2003 Mar; 48(3):780-90. PubMed ID: 12632433
[TBL] [Abstract][Full Text] [Related]
18. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
19. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method.
Svane IM; Nikolajsen K; Hansen SW; Kamby C; Nielsen DL; Johnsen HE
Bone Marrow Transplant; 2002 Apr; 29(8):659-66. PubMed ID: 12180110
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment.
Raja KR; Plasil M; Rihova L; Pelcova J; Adam Z; Hajek R
Cytometry B Clin Cytom; 2014 Jul; 86(4):220-8. PubMed ID: 23922218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
